Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.
复制标题
DOI：
10.3109/09546634.2012.755255
复制
发表时间：
2013-10
期刊：
影响因子：
--
通讯作者：
Gandra SR
中科院分区：
文献类型：
--
作者：
Bonafede M;Johnson BH;Fox KM;Watson C;Gandra SR
本研究考察了依那西普和阿达木单抗在银屑病、银屑病关节炎或两者兼有患者中的真实治疗模式。该回顾性分析使用了来自美国大型索赔数据库的银屑病、银屑病关节炎或两者患者的数据。结局指标包括索引治疗的持续性;治疗暂停（7-59天）和间隔（≥60天）;以及非持续性患者中索引治疗的中止率、转换率和重新开始率。在4，453例患者中，2，534例开始使用依那西普，1，919例开始使用阿达木单抗。在银屑病患者（n = 2，775）中，依那西普和阿达木单抗分别有46.4%和56.8%的患者持续≥12个月，49.0%和56.3%的患者中止治疗，23.8%和22.4%的患者重新开始治疗，14.9%和11.3%的患者在12个月内转换索引治疗。在银屑病关节炎患者（n = 1，197）中，依那西普和阿达木单抗分别有60.7%和63.3%的患者持续≥12个月，48.3%和51.6%的患者中止治疗，25.8%和20.0%的患者重新开始治疗，16.5%和17.9%的患者转换索引治疗。在同时存在这两种情况的患者中（n = 481），依那西普和阿达木单抗分别有58.1%和59.6%的患者持续≥12个月，42.7%和63.2%的患者中止治疗，24.3%和12.6%的患者重新开始治疗，21.4%和15.8%的患者转换索引治疗。在开始依那西普或阿达木单抗治疗后12个月内，银屑病、银屑病关节炎或两者兼有的患者中，治疗调整很常见。
This study examined real-world etanercept and adalimumab treatment patterns in patients with psoriasis, psoriatic arthritis, or both. This retrospective analysis utilized data from patients with psoriasis, psoriatic arthritis, or both from a large, US claims database. Outcome measures included persistence on index therapy; pauses (7–59 days) and gaps (≥60 days) in therapy; and rates of discontinuing, switching and restarting index therapy in nonpersistent patients. Of 4,453 patients, 2,534 initiated etanercept and 1,919 initiated adalimumab. In psoriasis patients (n = 2,775), 46.4% and 56.8% on etanercept and adalimumab, respectively, were persistent for ≥12 months, 49.0% and 56.3% discontinued, 23.8% and 22.4% restarted and 14.9% and 11.3% switched index therapy within 12 months. In psoriatic arthritis patients (n = 1,197), 60.7% and 63.3% on etanercept and adalimumab, respectively, were persistent for ≥12 months, 48.3% and 51.6% discontinued, 25.8% and 20.0% restarted and 16.5% and 17.9% switched index therapy. In patients with both (n = 481), 58.1% and 59.6% on etanercept and adalimumab, respectively, were persistent for ≥12 months, 42.7% and 63.2% discontinued, 24.3% and 12.6% restarted and 21.4% and 15.8% switched index therapy. Treatment modifications were common in patients with psoriasis, psoriatic arthritis, or both within 12 months of initiating etanercept or adalimumab.
登录
查看更多内容
影响因子：
3.8
作者：
Chastek, Benjamin;Fox, Kathleen M.;Gandra, Shravanthi R.
通讯作者：
Gandra, Shravanthi R.
影响因子：
13.8
作者：
Menter, Alan;Korman, Neil J.;Bhushan, Reva
通讯作者：
Bhushan, Reva
影响因子：
--
作者：
Kim, Noori;Thrash, Breck;Menter, Alan
通讯作者：
Menter, Alan
影响因子：
4.9
作者：
Saad AA;Ashcroft DM;Watson KD;Hyrich KL;Noyce PR;Symmons DP;British Society for Rheumatology Biologics Register
通讯作者：
British Society for Rheumatology Biologics Register
影响因子：
27.4
作者：
Gladman, DD;Antoni, C;Nash, P
通讯作者：
Nash, P